Company profile
Samphire Neuroscience
Anon-invasive medical solution for symptoms associated with PMS, PMDDand menstrual pain. Currently undergoing certifications, releasing soon.
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQzNDQ3MTUyNWFkaXF6a2N4
Published 04 Sep 2024 10:15
Company registered at Companies House
1 Jun 2024 to 31 May 2025
SamphireXR is an innovative digital therapeutic solution, designed to address the mental health challenges faced by peri-menopausal women, a group that has historically been underserved in healthcare. With insomnia and anxiety being significantly more prevalent in women -- particularly around menopause -- SamphireXR emerges as a deeply needed intervention...
1 May 2024 to 30 Apr 2025
A large majority of reproductive-age women experience menstruation-related symptoms and have missed work as a result, which has led to a loss of productivity through sickness, absence and underperformance by those women who go to work while feeling unwell. The annual cost of this productivity loss in the UK has been estimated at £17.4B. Current options fo...
1 Dec 2022 to 31 May 2024
Samphire is a UK medical device SME with a core project team of Emile Radyte (CEO/project lead), Alexander Cook (COO/commercial lead) and Ervinas Bernatavicius (product manager/technical lead). A large majority of reproductive-age women experience menstruation-related symptoms and have missed work as a result, which has led to a loss of productivity throu...
